Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04421820
Title BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bold Therapeutics, Inc.

colorectal cancer

stomach cancer


pancreatic cancer

gastrointestinal system cancer


BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.